Refractory Multiple Myeloma Treatment Market To Exhibit Significant Incremental Dollar Opportunity During The Forecast Period 2019 - 2029

10/feb/2020 11:02:00 persistencemarketresearch Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Multiple myeloma is a disorder in malignant plasma cell which mostly affects secondary organs such as bone, renal, bone marrow, immune as well as neurologic dysfunction. Multiple myeloma is a malignancy in clonal plasma cell that results from complex interactions between bone marrow stromal cells, malignant progenitor cells and the bone marrow microenvironment. Refractory multiple myeloma can be defined as a disease that is progressive or non-responsive on therapy or within sixty days of last treatment in patients with less response.

According to Janseen report 2016, an estimate of 38,000 new multiple myeloma cases were recorded each year in Europe. In addition to that, 28% multiple myeloma patients die within a year of diagnosis.

Refractory multiple myeloma treatment is expected to register significant growth in the market owing to increasing prevalence of multiple myeloma, advancement in research and development for innovative therapeutics for the refractory multiple myeloma treatment, introduction of monoclonal antibody for refractory multiple myeloma treatment are some of the factors driving the growth of the refractory multiple myeloma treatment market . However, currently there is no standard of care for refractory multiple myeloma treatment.

To Remain 'Ahead' Of Your Competitors, Request for a Sample Here @ https://www.persistencemarketresearch.com/samples/29806

Moreover, cost associated with refractory multiple myeloma treatment and huge expenses in research and development in bringing out novel therapeutics may hinder the growth of the refractory multiple myeloma treatment market.

The global refractory multiple myeloma treatment market is segmented on the basis of treatment type and distributional channel

  • Refractory Multiple Myeloma Treatment Market Segmentation by Treatment
    • Immunomodulatory drugs (IMiDs)
      • Thalidomide (THAL)
      • Lenalidomide
      • pomalidomide
      • Bortezomib
      • carfilzomib
    • Cytotoxic agents
    • High-Dose Therapy And Autologous Stem Cell Transplantation (HDT-SCT)
    • Allogeneic Stem Cell Transplantation
  • Refractory Multiple Myeloma Treatment Market Segmentation by Distributional Channel
    • Hospitals
    • Cancer Institutes
    • Ambulatory Surgical Centers
    • Others

 

Access Full TOC of This Report @ https://www.persistencemarketresearch.com/toc/29806

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl